NCAM1 and sarcoidosis: The current study was designed to measure the therapeutic effects of infliximab on the expression of NK cells, CD56+ T cells, and B cells in the lung and circulation in patients with sarcoidosis by performing bronchoscopy with BAL and collecting blood samples close adjacent to the start of treatment and after 6 months of treatment.